# A Study to See the Effects That a New Combination of the Three Drugs, Nab-paclitaxel, Gemcitabine, and Cisplatin Has on Biliary Tract Cancer

> **NCT02632305** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **AHS Cancer Control Alberta** · enrollment: 45 (actual)

## Conditions studied

- Unresectable Biliary Tract Cancer

## Interventions

- **DRUG:** nab-paclitaxel in combination with gemcitabine + cisplatin

## Key facts

- **NCT ID:** NCT02632305
- **Lead sponsor:** AHS Cancer Control Alberta
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-07-13
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2025-06-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02632305

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02632305, "A Study to See the Effects That a New Combination of the Three Drugs, Nab-paclitaxel, Gemcitabine, and Cisplatin Has on Biliary Tract Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02632305. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*